Tests sitagliptin or BeiDouGen capsules in women with polycystic ovary syndrome
Tests sitagliptin, BeiDouGen capsules, or both in women with polycystic ovary syndrome.
Plain-language title generated from the registry record
Registry title: Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 20-40 with PCOS who plan to conceive or are infertile, and who are followed at the clinic.
- Age
- 20-40 years
- Sex
- Women only
- Disease stage
- PCOS diagnosed by the Rotterdam criteria: at least two of three signs (rare or no ovulation, signs of high male hormones, polycystic ovaries on ultrasound).
- Earlier treatment
- No weight loss drugs or weight loss surgery in the past 3 months. No insulin, blood sugar drugs or beta-blockers in the past 3 months. No steroid, anti-androgen, birth control pill, ovulation drug or hormone-affecting drugs in the past 2 months.
Main reasons for not taking part
- Pregnant, breastfeeding or postmenopausal women
- Other diseases that cause high male hormones or ovulation problems
- Chronic diseases needing regular medication, such as high blood pressure or diabetes
- Severe liver, kidney, heart, brain or stomach and bowel disease
- Hepatitis B e antigen-positive, active tuberculosis or HIV
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
Source: NCT06587698, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaContact: Jie QiaoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT06587698
- Record updated
- 19 September 2024
- Original description
This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related researchRead full original descriptionShow less
Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research
Inclusion: Female patients aged 20-40 years who plan to conceive or are infertile in our center; Diagnosed with PCOS according to the Rotterdam criteria: Diagnosis of PCOS can be made if two out of the following three criteria are met: (1) Oligoovulation or anovulation, (2) Clinical or biochemical signs of hyperandrogenism, (3) Polycystic ovaries on ultrasound examination; Patients who are regularly followed up at our clinic. No participation in other research projects currently or in the past 3 months.
Exclusion: Pregnant, lactating, or postmenopausal women. Taking weight loss medications or undergoing weight loss surgery in the past 3 months or currently; Use of glucocorticoids, anti-androgenic drugs, oral contraceptives, ovulation-inducing drugs, weight loss drugs, or other medications affecting hormone levels, appetite, and carbohydrate metabolism in the past 2 months; Patients currently or previously with severe cardiovascular and cerebrovascular diseases that may interfere with the normal conduct of the trial (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmias, patients undergoing interventional therapy, etc.); Cancer patients or those who have received radiation and chemotherapy within the past five years; Food allergies. Other diseases that may cause hyperandrogenism or ovulation abnormalities (e.g., Cushing's syndrome, non-classical congenital adrenal hyperplasia, tumors secreting androgens in the ovaries or adrenal glands, functional hypothalamic amenorrhea, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency, etc.); Use of insulin, hypoglycemic drugs, or beta-blockers in the past 3 months. Patients with chronic diseases such as hypertension, gout, hyperuricemia, diabetes, etc., requiring regular medication; Patients currently with severe gastrointestinal diseases such as gastrointestinal ulcer bleeding, chronic diarrhea, or who have undergone gastrointestinal resection surgery, which may affect nutrient absorption; Patients with infectious diseases such as hepatitis B e antigen-positive, active pulmonary tuberculosis, or HIV; Patients with any psychological or psychiatric disorders requiring medication, including epilepsy patients or those undergoing antiepileptic treatment, patients using antidepressants, etc; Patients with liver cirrhosis or various severe liver diseases (alanine aminotransferase and/or aspartate aminotransferase exceeding 3 times the upper limit of normal), patients with abnormal renal function (serum creatinine exceeding the upper limit of normal), patients with kidney disease or other diseases requiring control of protein intake; Daily alcohol consumption exceeding 15g. Smoking habit; -.